David Y Zhang, MD, PhD Email David Zhang
- PROFESSOR | Pathology
- PROFESSOR | Oncological Sciences
- ASSOCIATE PROFESSOR | Environmental Medicine & Public Health
Apoptosis/Cell Death, Cancer, Cell Cycle, Drug Design and Discovery, Molecular Biology, Nanotechnology, Pathology, Proteomics
MPH, Mount Sinai School of Medicine
PhD, NYU School of Medicine
Anatomic and Clinical Pathology, Cytopathology, Molecular Genetic Pathology, Preventive Medicine (Occupational Medicine)
Specific Clinical/Research Interest:
Clinical Interest: Providing molecular diagnostic tests in the areas of cancer prognosis and therapy, pharmacogenetics, hematologic disorders,and infectious diseases.
Interest: Molecular cancer biology with focus on cancer biomarker discovery and
technology development including genomics and proteomics for cancer diagnosis
Current Students: Xiufen Liu, Wei Li, Wuhan Hui
Postdoctoral Fellows: Weihua Tong MD, PhD
Research Personnel: Fei Ye PhD, Clinical Assistant Professor; Josephine Wu DDS, JD, Assistant professor
Summary of Research Studies:
We developed a signal transduction pathway-focused proteomic method, termed PROTEIN PATHWAY ARRAY (PPA), which can be used to globally screen the signaling proteins and their activation. With the assistance of computation, we are able to identify key node, hubs, pathways and signaling network that controls cell proliferation, apoptosis, angiogenesis, necrosis, etc. This method has been used to identify novel candidate proteins as cancer biomarkers for diagnosis and prognosis and/or as targets for cancer treatment. We also invented several DNA amplification technologies, including the rolling circle amplification (RCA), isothermal ramification amplification assay (RAM) and hybridization signal amplification (HSAM). These technologies have been granted by the US Patent Office and licensed to Hamilton Thorne Biosciences, a biotechnology company based in Boston. RAM, unlike conventional polymerase chain reaction (PCR), can amplify DNA, RNA and protein without the use of thermocycling. It is extremely sensitive and can detect as few as 10 molecules. HSAM is another signal amplification technology based on the principles of nucleic acid hybridization and specific ligand interaction. This technology is simple and sensitive to identify DNA/RNA targets and proteins and can be apply to in situ amplification, DNA arrays, and proteomics.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Zhang has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.